Who’s Hired? Firms Ring In 2023 With Fresh Faces
Sandoz, Stada and Viatris Are Among Firms Announcing New Appointments
The start of 2023 has seen a number of firms across the off-patent industry announce management changes, with multiple appointments at Sandoz, a new CFO at Stada, a fresh CSO at Mallinckrodt, new generics leadership at Orion and board changes at Viatris and EuroAPI.
You may also be interested in...
Sandoz and Astellas have struck a deal that will see the Novartis subsidiary acquire global rights to the Mycamine micafungin antifungal brand, bolstering Sandoz’s anti-infectives portfolio and hospital offering.
Executive changes in 2022 reveal how the industry is adjusting to a volatile post-COVID environment.
Amneal has delivered on promises that it would soon finalize a European partnership by announcing a long-term licensing collaboration with Finnish firm Orion that will also cover Australia and New Zealand.